Nivolumab or atezolizumab in the second-line treatment of advanced non-small cell lung cancer? a prognostic index based on data from daily practice

HIGHLIGHTS

• who: Magdalena Knetki-Wru00f3blewska et al. from the Department of Lung Cancer and Chest Tumours, The Maria Sku0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland have published the paper: Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice, in the Journal: (JOURNAL)
• what: The authors aim to confirm the benefits and indicate predictive factors for immunotherapy in daily Methods: This study was a retrospective analysis. The aim was to identify the clinical and morphological factors that can define the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.